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BLOOD AND BLOOD SUBSTITUTES
A. DOBNICKE, B. GROTE AND W. LORENZ
Each year, in Europe, approximately seven million
units of colloidal plasma substitutes are given to
patients. Often they are used uncritically, which
may account for the increased incidence of side-
effects which has been noted over the last decade.
Their increasing use is understandable in view of
the disadvantages of using blood; these include the
difficulties in finding sufficient donors of all the
blood groups, the problems of storage of blood
and the inherent risks of blood transfusion which
include the immunological and toxicological
hazards. It should not be forgotten that there are
advantages in replacing lost blood with whole blood
or blood fractions. These include the similarity of
the substitute to the lost fluid, the ability to bind,
transport and deliver oxygen to the tissues and the
ability to take over the various biochemical functions
of the lost body fluids.
BLOOD
Fourtunately, humans normally contain some 25%
more haemoglobin than they actually need. The
ideal balance between the oxygen transporting
capacity of the circulation and the viscosity of the
blood is probably better attained when the haemato-
crit is 30% rather than the more usual 45%
The primary indication for transfusion is, of
course, blood loss. In deciding whether to use blood
or plasma substitutes as the replacement fluid, it is
necessary to consider the prior condition of the
patient. The oxygen carrying capacity of any
individual is a function of both the cardiac output
and the oxygen concentration of the arterial blood,
therefore cardiac reserves need to be taken into
consideration. In normal patients a loss of some 20%
of the blood volume or a decrease in the haemoglobin
concentration to some 9-10 g/dl is well tolerated.
The associated volume loss can be managed using
plasma substitutes. The limitations to this technique
will be seen in patients whose general conditions
are poor.
Replacement of intraoperative blood loss with
albumin solutions appears to be superior to replace-
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merit with dextran solutions (Kallos and Smith,
1974). The total blood loss is less and the need for
a transfusion after operation is diminished.
Objective quantitative determinations of blood
loss are generally not necessary (Gardiner and Dudley
1962; Underwood, Gowing and Johnston, 1967;
Moe, 1970), but because of the particular conditions
encountered in infants and small children it is
desirable to use either a gravimetric or a photometric
method to estimate the actual loss from those
patients (Wawersik, 1965).
Blood banks have become almost universally
available in the past 30 years. In consequence there
is often a thoughtless use of stored blood. After a
protest by the Canadian Red Cross in 1973 it was
found that 24% of stored blood issued was returned
unused and that some 5.5% was lost! The uncritical
use of blood is no longer justifiable and with the
use of sterile systems with numerous bags it is
possible to use the various blood components for
specific treatment. The problems related to this
have been presented in detail elsewhere (Symposium,
1966).
Blood transfusions may also be needed in anaemic
patients. Gillies (1974) has reviewed the problems
of anaemia and anaesthesia, which therefore will
not be discussed further here.
Complications of massive transfusion
Massive transfusion, that is an exchange of the
entire blood volume or more, will necessarily produce
complex changes in metabolism and in the coagulation
factors. Such complications can be lethal. The
diagnostic and therapeutic problems involved have
been described in detail by Bunker (1966) and
Miller (1973).
Much attention has been given to the survival of
the erythrocytes after transfusion, and less to their
function. In the past decade the key role of 2:3
diphosphoglyceric acid (2:3 DPG) has been under-
stood (Benesch and Benesch, 1967). Its concentration
decreases rapidly in stored blood, thereby shifting
the oxyhaemoglobin dissociation curve to the left
and impeding the delivery of oxygen from blood
to the tissues. Therefore transfusion of red cells will
not necessarily mean that there is an improved
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transport of oxygen to the tissues. The recovery
of normal red cell function requires at least 4 h
(Beutler and Wood, 1969) and, after massive trans-
fusion, may take 4-7 days (McConn and Derrick,
1972; Hausdoerfer et al., 1976). The freshest blood
available should therefore be used to reduce this
problem. In emergency situations this may not be
possible.
Temperature. The warming of stored blood to body
temperature during transfusion has reduced the
frequency of ventricular arrythmias and cardiac
arrest (Boyan, 1964). Boyan recommended that
warming was necessary only when massive trans-
fusions were given, finding that the oesophageal
temperature decreased by only 1 °C after the trans-
fusion of 5 units of cold blood in 90 min. Neverthe-
less, most workers suggest that all blood transfused
should be warmed to minimize the shivering seen
after operation which increases the oxygen consump-
tion at a time when cardiac performance may be
reduced.
pH. Storage of blood in ACD solutions increases
its acidity; in addition, metabolism during the
storage period progressively reduces the pH. However,
following massive transfusion the acid-base state
of the patient can fluctuate within wide limits such
that a routine administration of sodium bicarbonate
is not justified (Miller, Tong and Robbins, 1971).
Any correction of the acid-base state should be
based on analysis of arterial blood, which may be
necessary after the transfusion of each 5 units of
blood.
Citrate intoxication. The dangers of citrate in-
toxication have been overrated (Miller, 1973).
Only when more than 100 ml/min of blood is trans-
fused will there be a significant but transient decrease
in the serum calcium concentration (Denlinger et al.,
1976). The prophylactic administration of calcium
needs to be considered only in hypothermia or when
there is a disturbance of hepato-renal function.
Changes in the e.c.g. will probably be the best guide.
Shock lung. Many factors need to be considered
in elucidating the cause of "shock lung". Certainly
one possibility is the obstruction of the pulmonary
vascular bed with aggregates from the transfused
blood (McNamara et al., 1972). After about 5 days
of storage there is a significant increase in the number
of aggregates in blood (Harp et al., 1974). Micro-
filters will retain these particles (Reul et al., 1973).
There are differences between the filters commercially
available, and it seems that surface filters are to
be preferred (Cullen and Ferrara, 1974; Dunbar,
Price and Canarella, 1974; Buley and Lumley,
1975; Marshall et al., 1976).
Antibody formation. Massive transfusion will lead
to the formation of iso-antibodies in increasing
numbers. The incidence recorded in the literature
fluctuates between 1 and 3% (Grobbelaar and Smart,
1967; Maurer and Biittner, 1975; Schricker and
Kluge, 1976). Anti-D, anti-Kell and anti-E antibodies
were found. With time it is likely that the incidence
of finding these antibodies will increase as increasing
numbers of patients are given transfusions. Iso-
antibodies are frequently found in older patients
and in women. They should be sought in any patient
who has had a transfusion and who may need
another.
Plasma substitutes and blood typing. With massive
blood loss it will always be necessary for some of
the replacement fluid to be blood, even when plasma
expanders are used initially. Contrary to earlier
reports, the expanders in current use do not produce
difficulties in typing or cross-matching, provided
that the standard methods are used correctly (Pausch,
1974;. Kleine, 1975).
Transfusion hepatitis. Hepatitis following trans-
fusion is still an uncontrollable risk. Careful selection
of donors and the elimination of those who are
Australia antigen positive has not eliminated the
risk. The reported incidence of hepatitis following
transfusion varies from 0.16 to 6%. In addition,
the use of washed red cells has not reduced the risk
(Gotz, Thoma and Schafer, 1975). Following the
transfusion of more than 4 units of blood, the risk
of hepatitis increases by a factor of 2 or 3 (Mosley
and Dull, 1966). The production of pooled plasma
has largely been abandoned because of the high
risk. However, the albumin solutions prepared com-
mercially or by the blood banks are considered safe.
Auto-transfusion
Three techniques are available to eliminate the
risks associated with the transfusion of blood from
donors.
Preoperative removal and storage. This method,
whereby blood is taken from the patient before
operation, is limited by the possibility of storing
blood for up to only 3 weeks. Experience has shown
that it is possible to obtain a number of units of
blood from any one patient in this time. Milles,
Langston and Dallessandro (1971) began by taking
only 500 ml of blood but developed a practice of
collecting 3 units, each taken at 2-day intervals,
with the last collected 4 days before the operation.
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A more complex method which can be applied,
especially to patients with rare blood groups, is
to take the estimated requirement and preserve the
cells by deep freezing. The drawbacks for this
method are its limitation to a few centres, its expense
and the fact that the thawed cells must be used
within 24 h.
Peroperative collection and haemodilution. In the
past few years plasma substitutes have shown then-
value in the technique of haemodilution. The
principal advantage is that autologous blood is
stored beside the patient and can be re-transfused at
any time. This can be compared with the disadvant-
ages of transfusing homologous blood. Haemodilution
is best carried out by replacing the blood taken with
equal parts of albumin and dextran solutions. Under
these circumstances there is no increased incidence
of bleeding after operation. The advantages and
disadvantages of this technique have been discussed
in the April 1976 issue of Anaesthesist. Whilst a
dilution of blood to a haematocrit of 25% is generally
tolerated well, it may not be safe in some patients
with cardiac complaints.
Introoperative autotransfusion. The autotransfusion
of autologous blood has been used during the past
century and a half but, with the ready availability of
stored blood, has become largely ignoredas a technique.
It has been used in the United States (Stehling,
Zander and Rogers, 1975) and has caught on in
many centres in Germany (Feist et al, 1976; Kieninger
Junger and Schmidt, 1976; Homann, Klaue and
Kult, 1977). The technique may be especially useful
in countries in which, for various reasons, the prep-
aration of stored blood is problematical.
There are various circumstances in which auto-
transfusion is extremely useful, such as the frequent
large blood losses associated with vascular surgery
and with trauma in the thorax and abdomen, in
operations on the liver and in ectopic pregnancies.
Contraindications include operations for tumours
and for septic abdominal conditions, although the
method has been used without complications
following trauma to the kidney, bladder and intestines
(Kieninger, Junger and Schmidt, 1976). There is
a considerable risk of air embolism and any system
used must be carefully supervised. Although the
plasma haemoglobin concentration increases with
this method, there have been no reports of renal
failure where a supportive osmotic diuresis has been
used at the same time.
The changes produced in blood coagulation by
the technique resemble those seen after a homologous
massive transfusion and the experience of those
workers cited above shows that the destruction of
the coagulation factors by contact with foreign
surfaces in the apparatus is slight.
PLASMA SUBSTITUTES
The plasma substitutes of greatest clinical use are:
the natural colloids (plasma protein solutions,
human albumin) and the synthetic colloids (dextrans,
gelatins and hydroxyethyl starches) prepared from
materials derived from animals or plants. Moffitt
(1975) has suggested that any synthetic colloid
should have the following desirable properties.
First, it should maintain an adequate colloid osmotic
pressure with a half-life of several hours. Second,
it should be stable and capable of being stored for
long periods independent of the storage temperature.
Third, it should be free of pyrogens and antigens.
Finally, its metabolism and elimination should not
affect the organism and it should not cause haemolysis
or red cell agglutination. The substitutes now available
fulfil some of these conditions, but other effects
have appeared which have led to a flood of partially
contradictory publications in the past few years.
The following are the most important, commonly
used, commercially available plasma substitutes:
Dextran. Dextrans are produced by the bacterium
Leuconostoc mesenteroides B512 from an agar-sugar
compound to which a yeast extract is added as a
source of nitrogen. In preparing dextran solutions
the degree of variation in t ie polysaccharide chains
is important as well as the average molecular weight.
Dextran 40 has a mean molecular weight of 40 000
and Dextran 60 and 70 molecular weights of 60 000
and 70 000, respectively.
Gelatin. Gelatins are prepared by the hydrolysis
of animal collagens (bones, etc.). There are three
modified solutions available: a modified fluid
gelatin, a urea-linked gelatin and an oxypoly gelatin.
Starch. Starch solutions prepared by the acid
hydrolysis of corn or soya may be used as plasma
expanders only after the introduction of hydroxyethyl
groups into the glucose units. To obtain a satis-
factory half-life in the circulation the commercially
available solutions have hydroxyethyl units attached
to 70% of the glucose units.
Indications for use of plasma substitutes
The principal indication for the use of colloid
plasma substitutes is in the treatment of hypo-
volaemia. They have shown their value in the
treatment of shock following accidents. There are
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TABLE I. Production and properties of different colloidal plasma substitutes
Substitute
Plasma protein
Dextran
Gelatin
Starch
Production
Human plasma,
placenta
B. Leuconostoc mesen-
teroids B512 on agar-
sucrose plates
Hydrolysis from animal
collagens
Acid hydrolysis and
ethylene oxide treat-
ment of soya and
corn
Types
Serum conserves
Human albumin
(5% and 20%)
D 60/75
D40
Modified gelatin
Urea-linked
Oxypolygelatin
Hydroxyethylene
starch
Mean
molec. wt.
50 000
60 000
40 000
35 000
450 000
Intra vascular
half-life
4-15 days
6h
2-3 h
2-3 h
6h
Indications
Volume substitution,
hypoproteinaemia,
haemodilution
Haemodilution
Microcirculation dis-
turbances
(Both:) Volume sub-
stitution, throm-
bosis prophylaxis
Volume substitution
Volume substitution,
haemodilution
large differences between the various solutions in
terms of the changes they produce in blood volume
and in the duration of their effects (table I). For
example, the duration of action of Dextran 60 is
about 6 h as is that of hydroxyethyl starch (HES),
whilst gelatins and Dextran 40 last only 2-3 h.
The increase in blood volume is least with gelatin.
Strey and his colleagues (1977) have studied the
effects of plasma subtitutes and noted initially that
90 min after the removal of 1 litre of blood the
reduction in the measured plasma volume was only
200 ml. Therefore 400 ml or so of fluid must have
entered the plasma from the extravascular spaces
in that period. The infusion of 1 litre of Dextran 60
led to small increases in plasma volume and blood
volume above the initial values. It took 4 h for the
blood volume to be restored to the initial control
value. Strey and colleagues (1977) also measured
the duration of the effect of dextran. About 56% of
the infused dextran was still in the blood 4 h after
termination of the infusion. This represents 34 g of
dextran which would hold 700 ml of water. In
addition, they showed that this infusion produced a
decrease in the peripheral systemic resistance with
an increase in venous return and cardiac output.
These effects must be beneficial for tissue perfusion
and were detectable especially in the renal effects.
In this context it is interesting to compare the
serum concentrations of Dextran 60 and HES found
by Boon and colleagues (1976) in a study in volunteers.
The elimination of HES from the blood followed a
protracted course. Two weeks after the infusion
the HES concentration was still 9% of the initial
value and at 17 weeks was still greater than 1%. In
contrast, Dextran 60 was undetectable 4 weeks after
its infusion.
In addition to the use in hypovolaemia there are
some additional indications for using plasma protein
solutions and dextrans. Plasma protein solutions
can be used where there is hypoproteinaemia or
where plasma clotting factors are deficient. The
two other features of dextrans are their antithrom-
botic effect and, especially with Dextran 40, the
effect of improving the microcirculation.
Gruber and his colleagues (1975) have shown in
28 randomized controlled studies, that the incidence
of thromboembolic venous thrombosis was 35% in
patients undergoing general surgery, but that when
dextrans were given during or after operation the
incidence was reduced significantly.
The improvement of the microcirculation by the
infusion of hyperoncotic Dextran 40 is of use in
the treatment of peripheral and cerebral perfusion
disturbances (Herrschaft, 1975; Gottstein, Sedlmeyer
and Heuss, 1976).
Reactions to plasma substitutes
There are incompatibility reactions to plasma
substitutes; they are diverse in nature and need to
be studied in detail. The reported incidence of such
reactions varies between 2.0% (Rudowski et al.,
1973) and 19% (Schoning and Koch, 1975). The
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increased reported incidence of reactions leads us to
assume that there is an actual increase. In order
to examine this problem, Ring and Messmer (1977)
performed a controlled prospective comparative study
in 31 hospitals in Southern Bavaria. They observed 69
anaphylactoid reactions following 100 906 units of the
commonly used colloidal plasma substitutes. There
were differences between the agents: following plasma
proteins there were reactions in 0.014% of patients,
following dextran in 0.032%, following gelatins in
0.115% and following hydroxyethyl starch in 0.085%.
The types of anaphylactoid reaction seen varied
in intensity from skin reactions with flushing and
mild urticaria to more severe effects such as shock
and cardiac and respiratory arrest (Lorenz et al.,
1976). Ring and Messmer (1976) divided such
reactions into four types (table II). The frequencies
of life-endangering reactions were: 0.003% for
TABLE II. Severity scale for quantification of intensity of
anaphylactoid reaction
Grade Symptoms
I Skin symptoms or mild fever reaction, or both
II Measurable, but not life-threatening
Cardiovascular reaction (tachycardia, hypoten-
sion)
Gastrointestinal disturbance (nausea)
Respiratory disturbance
III Shock, life-threatening spasm of smooth muscles
(bronchi, uterus, etc.)
IV Cardiac or respiratory arrest, or both
plasma proteins, 0.008% for dextran, 0.038% for
gelatins and 0.001% for hydroxyethyl starch. These
data and our personal observations (Lorenz et al.,
1971, 1976; Doenicke, 1976) lead us to conclude
that no colloid substitute can be given without risk.
Lorenz and his colleagues (1977) have determined
the extent to which histamine release is involved in
these reactions and investigated whether it is the
predominant mediator. A randomized controlled
trial was carried out in humans and dogs. The humans
received either Dextran 60, gelatin cross-linked by
hexamethylene diisocyanate (Haemaccel), oxypoly-
gelatin (Gelifundol) or high molecular weight
hydroxyethyl starch (Plasmasteril). The dogs were
given either dextran 60, Haemaccel, Gelifundol,
Plasmasteril, gelatin cross-linked by succinic acid
anhydride (Neoplasmagel) and phosphatidyl serine
(PS), dextran 60 and PS or Plasmasteril and PS. In
the humans plasma histamine concentrations (Lorenz
55
et al., 1972) were measured together with the heart rate
and arterial pressure and in the dogs the whole blood
histamine concentrations (Lorenz et al., 1974) and the
arterial pressures were measured together with investi-
gations into the macroscopical and microscopical
pathology. In man all four plasma substitutes released
small, clinically unimportant, amounts of histamine.
This was unrelated to the occurrence of urticaria except
with Haemaccel. One girl developed a generalized urti-
caria following the oxypolygelatin infusion, but
this was not associated with any increase in plasma
histamine.
Similar results were obtained in the dogs. When
Haemaccel produced hypotension this was accom-
panied by a correspondingly large increase in whole
blood histamine. Severe hypotension occurred less
frequently with the other substitutes and was not
accompanied by the release of histamine. Phospha-
tidyl serine did not release histamine in dogs, but
there was a greater release when it was combined
with dextran or hydroxyethyl starch than when
these expanders were used alone.
The skin reactions with the plasma substitutes in
man did not show any relation to the histamine con-
centrations. This might be a result of either the re-
actions not being caused by histamine release, or the
release in the skin being small and insufficient to
show systemic effects and increased plasma con-
centrations, although adequate for the skin reaction.
It was concluded that histamine can be released
in humans by gelatin (Haemaccel) and to a smaller
degree by dextran. When accidents occured in
clinical practice histamine was found in every case
when Haemaccel was used. In two severe incidents
with dextran (one fatal) no significant increase in the
plasma histamine concentration was found.
It seems, therefore, that reactions to Haemaccel are
related to the release of histamine and are probably
the result of a direct effect of the drug on mast cells.
This may be clinically important with the develop-
ment of further specific Hx and H2 receptor antago-
nists which may give better control of such reactions.
Ring and Messmer (1977) believe that the severe
anaphylactoid reactions to dextran are probably
related to antidextran antibodies such as IgG and
IgM which have been found in high concentrations
in all patients with severe reactions. The recorded
reactions after hydroxyethyl starches may not be
caused by histamine release, but may involve kinins.
With their close similarity to starch, an anaphy-
lactoid reaction mediated by humoral mechanisms
might be the cause (Doenicke, 1976).
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TABLE III. Pathological mechanism of anaphylactoid reactions after colloidal infusion (Ring and
Messmer, 1977)
Colloid Reaction types Mechanism Authors
Plasma protein Immediate reaction Protein allergy, aggre-
gates
Dextran
Gelatin
Starch
Late reaction
Mild reaction
Severe reaction
Aggregates, stabilizers
Allergic disposition
Anti-Dextran antibodies
(IgG and IgM)
Complement activation
Immediate reaction Histamine release
Ring and others (1974)
Ring (1976)
Ring (1976)
Ring and Messmer (1977)
Johnson and Laurell (1974)
Lorenz and others (1971,
1976)
Doenicke and Lorenz (1977)
Immediate reaction Complement activation Ring and others (1976)
The term "anaphylactoid reaction" should be
understood in this context as any undesirable
hypersensitivity as shown by the classical anaphy-
lactic reactions. The reactions are individually
specific and independent of the mechanisms of
action of the drugs. Table III summarizes the re-
action and mechanisms for the differing plasma
substitutes.
In anaesthetic practice Bauer and Ostling's (1970)
observation, that most reactions occur immediately
after the infusion of only a few millilitre of the sub-
stitute, is important. Detailed observation is thus
necessary in this stage of treatment if major problems
are to be avoided.
In treating reactions we use the same rules as for
those seen with other anaesthetic drugs (Doenicke
and Lorenz, 1970). They seem to be equally effective
for plasma substitutes. If there is only mild urticaria,
stopping the infusion usually is all that is needed, but
if the urticaria is severe, calcium antihistamines and
corticosteroids should be used. In acute problems
with circulatory failure adrenaline 0.05-0.1 mg
should be given immediately with further injections
at 1-2 min intervals as required. High doses of
corticosteroids should also be given and the plasma
volume should be expanded using a human albumin
solution.
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